Roger Owen

2.3k total citations
48 papers, 1.7k citations indexed

About

Roger Owen is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Statistics and Probability. According to data from OpenAlex, Roger Owen has authored 48 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 22 papers in Physiology and 8 papers in Statistics and Probability. Recurrent topics in Roger Owen's work include Chronic Obstructive Pulmonary Disease (COPD) Research (29 papers), Asthma and respiratory diseases (22 papers) and Respiratory Support and Mechanisms (20 papers). Roger Owen is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (29 papers), Asthma and respiratory diseases (22 papers) and Respiratory Support and Mechanisms (20 papers). Roger Owen collaborates with scholars based in United Kingdom, United States and Germany. Roger Owen's co-authors include Benjamin Krämer, Mark Higgins, Cheryl Lassen, Damon Jack, Ronald Dahl, Oliver Kornmann, Steven A. Julious, Stefano Centanni, Donald A. Mahler and Amir Iqbal and has published in prestigious journals such as Journal of the American Statistical Association, Neurology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Roger Owen

43 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roger Owen United Kingdom 19 1.2k 1.1k 199 135 76 48 1.7k
Lori A. Thombs United States 19 87 0.1× 88 0.1× 86 0.4× 219 1.6× 7 0.1× 43 1.1k
Joseph G. Pigeon United States 14 46 0.0× 44 0.0× 84 0.4× 84 0.6× 9 0.1× 26 954
David E. Morris United Kingdom 14 63 0.1× 188 0.2× 14 0.1× 26 0.2× 18 0.2× 44 681
Zhaoyi Chen United States 18 110 0.1× 44 0.0× 15 0.1× 34 0.3× 16 0.2× 64 1.3k
Ove Wigertz Sweden 15 59 0.0× 75 0.1× 37 0.2× 8 0.1× 49 0.6× 88 969
Bruno Scherrer France 17 22 0.0× 143 0.1× 47 0.2× 118 0.9× 35 0.5× 53 1.5k
Lu Lin China 13 60 0.0× 43 0.0× 41 0.2× 243 1.8× 9 0.1× 51 979
D. Whitaker New Zealand 16 74 0.1× 39 0.0× 121 0.6× 37 0.3× 10 0.1× 41 911
Mathieu Lemay Switzerland 20 43 0.0× 48 0.0× 10 0.1× 43 0.3× 184 2.4× 96 1.1k
Jiajia Wang China 13 136 0.1× 116 0.1× 131 0.7× 15 0.1× 1 0.0× 67 659

Countries citing papers authored by Roger Owen

Since Specialization
Citations

This map shows the geographic impact of Roger Owen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Owen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Owen more than expected).

Fields of papers citing papers by Roger Owen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Owen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Owen. The network helps show where Roger Owen may publish in the future.

Co-authorship network of co-authors of Roger Owen

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Owen. A scholar is included among the top collaborators of Roger Owen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Owen. Roger Owen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Braithwaite, Irene, Jennifer Tom, Joshua Galanter, et al.. (2020). Inhaled JAK Inhibitor GDC-0214 Reduces Exhaled Nitric Oxide in Patients with Mild Asthma. A4272–A4272. 1 indexed citations
2.
Cope, Shannon, Gorana Capkun-Niggli, Cheryl Lassen, et al.. (2012). Efficacy of Once-Daily Indacaterol Relative to Alternative Bronchodilators in COPD: A Patient-Level Mixed Treatment Comparison. Value in Health. 15(3). 524–533. 11 indexed citations
3.
Jones, Paul, et al.. (2011). Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respiratory Medicine. 105(6). 892–899. 25 indexed citations
4.
Chapman, Kenneth R., et al.. (2011). Long-term Safety and Efficacy of Indacaterol, a Long-Acting β2-Agonist, in Subjects With COPD. CHEST Journal. 140(1). 68–75. 101 indexed citations
5.
Donohue, James F., Charles Fogarty, Jan Lötvall, et al.. (2010). Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease: Indacaterol Versus Tiotropium. American Journal of Respiratory and Critical Care Medicine. 182(2). 155–162. 273 indexed citations
6.
7.
LaForce, Craig, Joseph Aumann, L. de Teresa Parreño, et al.. (2010). Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: A randomized, crossover study. Pulmonary Pharmacology & Therapeutics. 24(1). 162–168. 24 indexed citations
8.
Feldman, Gregory, Thomas M. Siler, Damon Jack, et al.. (2010). Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulmonary Medicine. 10(1). 11–11. 101 indexed citations
9.
Dahl, Ronald, Kian Fan Chung, Roland Buhl, et al.. (2010). Efficacy of a new once-daily long-acting inhaled  2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 65(6). 473–479. 213 indexed citations
10.
Vogelmeier, Claus, David Ramos‐Barbón, Damon Jack, et al.. (2010). Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respiratory Research. 11(1). 135–135. 66 indexed citations
11.
Kornmann, Oliver, Ronald Dahl, Stefano Centanni, et al.. (2010). Once-daily indacaterolversustwice-daily salmeterol for COPD: a placebo-controlled comparison. European Respiratory Journal. 37(2). 273–279. 166 indexed citations
12.
13.
14.
Rennard, Stephen I., Theo A. Bantje, Stefano Centanni, et al.. (2008). A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respiratory Medicine. 102(7). 1033–1044. 71 indexed citations
15.
Pearlman, David S., et al.. (2008). Bronchodilator efficacy of indacaterol, a novel once-daily β2-agonist, in patients with persistent asthma. Annals of Allergy Asthma & Immunology. 101(1). 90–95. 25 indexed citations
16.
Kanniess, Frank, Louis‐Philippe Boulet, Władysław Pierzchała, et al.. (2008). Efficacy and Safety of Indacaterol, a New 24-hourβ2-Agonist, in Patients with Asthma: A Dose-Ranging Study. Journal of Asthma. 45(10). 887–892. 15 indexed citations
17.
Yang, William H., Jean‐Benoît Martinot, Petr Pohunek, et al.. (2007). Tolerability of indacaterol, a novel once-daily β2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Annals of Allergy Asthma & Immunology. 99(6). 555–561. 21 indexed citations
18.
LaForce, Craig, Michael J. Alexander, Leonardo M. Fabbri, et al.. (2007). Indacaterol provides sustained 24 h bronchodilation on once‐daily dosing in asthma: a 7‐day dose‐ranging study. Allergy. 63(1). 103–111. 35 indexed citations
19.
Julious, Steven A. & Roger Owen. (2006). Sample size calculations for clinical studies allowing for uncertainty about the variance. Pharmaceutical Statistics. 5(1). 29–37. 40 indexed citations
20.
Cain, Michael & Roger Owen. (1990). Regressor Levels for Bayesian Predictive Response. Journal of the American Statistical Association. 85(409). 228–231. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lori A. Thombs Breakdown of academic impact, for papers by Joseph G. Pigeon Breakdown of academic impact, for papers by David E. Morris Breakdown of academic impact, for papers by Zhaoyi Chen Breakdown of academic impact, for papers by Ove Wigertz Breakdown of academic impact, for papers by Bruno Scherrer Breakdown of academic impact, for papers by Lu Lin Breakdown of academic impact, for papers by D. Whitaker Breakdown of academic impact, for papers by Mathieu Lemay Breakdown of academic impact, for papers by Jiajia Wang
Rankless by CCL
2026